The serum concentration of Rosuvastatin can be increased when it is combined with Diethylstilbestrol. The risk or severity of adverse effects can be increased when Azelastine is combined with Fluocinolone Acetonide. The serum concentration of Levothyroxine can be increased when it is combined with Fusidic Acid. The serum concentration of Clobetasone can be increased when it is combined with Methallenestril. The serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Primidone. The risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyclizine. Indacaterol may increase the QTc-prolonging activities of Chlorpromazine. Magaldrate may decrease the excretion rate of Mephedrone which could result in a higher serum level. The serum concentration of Desoximetasone can be increased when it is combined with Atazanavir. The therapeutic efficacy of Alogliptin can be decreased when used in combination with Piperazine. The metabolism of Sunitinib can be decreased when combined with Econazole. Betaxolol may increase the orthostatic hypotensive activities of Labetalol. The risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyclizine. The risk or severity of adverse effects can be increased when Phentolamine is combined with Nitroglycerin. The serum concentration of Ketoprofen can be decreased when it is combined with Dabrafenib. The risk or severity of adverse effects can be increased when Fimasartan is combined with Indomethacin. The risk or severity of adverse effects can be increased when Tolazoline is combined with Bumetanide. The serum concentration of Memantine can be increased when it is combined with Bupropion. Hydrochlorothiazide may increase the hypotensive activities of Niguldipine. Pargyline may increase the hypotensive activities of Nisoldipine. The risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine. The serum concentration of Opium can be decreased when it is combined with Rilpivirine. The metabolism of Indapamide can be decreased when combined with Dihydroergotamine. The risk or severity of adverse effects can be increased when Ketoprofen is combined with Higenamine. Nepafenac may decrease the antihypertensive activities of Bevantolol. The risk or severity of adverse effects can be increased when Mizoribine is combined with Dexamethasone. Demeclocycline may increase the neuromuscular blocking activities of Rocuronium. The metabolism of Fenofibrate can be decreased when combined with Doxycycline. Molsidomine may increase the hypotensive activities of Metolazone. Pentolinium may increase the hypotensive activities of Zofenopril. The serum concentration of Alogliptin can be decreased when it is combined with Dabrafenib. The metabolism of Tamoxifen can be decreased when combined with Tolbutamide. The risk or severity of adverse effects can be increased when Difluocortolone is combined with G17DT. The therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylic acid. Oxymetholone may increase the hypoglycemic activities of Sitagliptin. The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pipotiazine. Bosentan may increase the hypotensive activities of Oxprenolol. Rasagiline may increase the hypotensive activities of Trichlormethiazide. The risk or severity of adverse effects can be increased when Zofenopril is combined with Nabumetone. The metabolism of Dapagliflozin can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Trimipramine is combined with Isoprenaline. Moxonidine may increase the hypotensive activities of Rescinnamine. Azelastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. The metabolism of Solifenacin can be decreased when combined with Miconazole. The serum concentration of Diclofenac can be decreased when it is combined with Secobarbital. Debrisoquin may increase the hypotensive activities of Dihydralazine. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Fenoldopam may increase the hypotensive activities of Trichlormethiazide. The metabolism of Doconexent can be decreased when combined with Sulfadiazine. Fluticasone furoate may increase the hypokalemic activities of Chlorthalidone. The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medrogestone. The risk or severity of adverse effects can be increased when Candesartan is combined with Phenylbutazone. The risk or severity of adverse effects can be increased when Rimexolone is combined with Galantamine. The risk or severity of adverse effects can be increased when Etanercept is combined with Flunisolide. The serum concentration of Drospirenone can be increased when it is combined with Clarithromycin. The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Asenapine. The metabolism of Fulvestrant can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methyclothiazide. The metabolism of Amlodipine can be increased when combined with Rifabutin. The metabolism of Aniline can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Clorazepate is combined with Lidocaine. The risk or severity of adverse effects can be increased when Opium is combined with Quinethazone. The risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine. The serum concentration of Tixocortol can be increased when it is combined with Chlorotrianisene. Phenylephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. The risk or severity of adverse effects can be increased when Valdecoxib is combined with Salicylamide. The metabolism of Tacrolimus can be decreased when combined with Nafamostat. The risk or severity of adverse effects can be increased when Losartan is combined with Evening primrose oil. Pentosan Polysulfate may increase the anticoagulant activities of Certoparin. The risk or severity of adverse effects can be increased when Terbinafine is combined with Cilnidipine. The serum concentration of Terbinafine can be decreased when it is combined with Mitotane. The serum concentration of Dabrafenib can be decreased when it is combined with Aluminum hydroxide. Flurbiprofen may decrease the antihypertensive activities of Metipranolol. The risk or severity of adverse effects can be increased when Sevoflurane is combined with Metolazone. The serum concentration of Estradiol can be decreased when it is combined with Artemether. The therapeutic efficacy of Tiotropium can be decreased when used in combination with Memantine. Amrubicin may increase the hypocalcemic activities of Etidronic acid. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Ceftriaxone. The metabolism of Rofecoxib can be decreased when combined with Sulfisoxazole. The serum concentration of Pioglitazone can be increased when it is combined with Abiraterone. The risk or severity of adverse effects can be increased when Cyclizine is combined with Dantrolene. The risk or severity of adverse effects can be increased when Tolmetin is combined with Halcinonide. The risk or severity of adverse effects can be increased when Acebutolol is combined with Doxofylline. The metabolism of Bisoprolol can be decreased when combined with Clarithromycin. Lisinopril may increase the hypotensive activities of Xylometazoline. The risk or severity of adverse effects can be increased when Oxprenolol is combined with Fospropofol. Icatibant may increase the hyperkalemic activities of Drospirenone. The risk or severity of adverse effects can be increased when Resveratrol is combined with Desonide. The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin. The metabolism of Piperazine can be decreased when combined with Clemastine. The serum concentration of Methallenestril can be decreased when it is combined with 1,10-Phenanthroline. Rosoxacin may increase the hypoglycemic activities of Empagliflozin. The risk or severity of adverse effects can be increased when Hexobarbital is combined with Methocarbamol. The risk or severity of adverse effects can be increased when Norepinephrine is combined with Nylidrin. The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketorolac. The serum concentration of Everolimus can be increased when it is combined with Fluvoxamine. The serum concentration of Ciclesonide can be increased when it is combined with Simeprevir. The metabolism of Enalapril can be decreased when combined with Itraconazole. Brimonidine may increase the antihypertensive activities of Hexamethonium. The serum concentration of Amitriptyline can be increased when it is combined with Saxagliptin. The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocortolone. Pizotifen may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Eltanolone is combined with Brompheniramine. The serum concentration of Methotrexate can be increased when it is combined with Masoprocol. The serum concentration of Losartan can be increased when it is combined with Osimertinib. The serum concentration of Telaprevir can be decreased when it is combined with Cortisone acetate. The risk or severity of adverse effects can be increased when Methazolamide is combined with Nadolol. The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bendroflumethiazide. The risk or severity of adverse effects can be increased when Perindopril is combined with Apremilast. The serum concentration of Rimexolone can be increased when it is combined with Promestriene. The risk or severity of adverse effects can be increased when Valsartan is combined with PTC299. The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethylmorphine. The metabolism of Acetaminophen can be decreased when combined with Clarithromycin. Isoxicam may decrease the antihypertensive activities of Metipranolol. The serum concentration of Simvastatin can be increased when it is combined with Alogliptin. The metabolism of Lidocaine can be decreased when combined with Gemfibrozil. Pargyline may increase the hypotensive activities of Deserpidine. Methyltestosterone may increase the hypoglycemic activities of Bromocriptine. The risk or severity of adverse effects can be increased when Cocaine is combined with Indiplon. The metabolism of Rucaparib can be decreased when combined with Cholecalciferol. The metabolism of Reboxetine can be decreased when combined with Atazanavir. Azelastine may decrease the excretion rate of Streptomycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Diltiazem is combined with Mannitol. Hydroxyzine may increase the QTc-prolonging activities of Ciprofloxacin. The risk or severity of adverse effects can be increased when Antipyrine is combined with Indobufen. The therapeutic efficacy of Insulin Human can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flumethasone. Pirlindole may increase the hypoglycemic activities of Dapagliflozin. Antipyrine may decrease the excretion rate of Streptozocin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Indobufen is combined with Collagenase clostridium histolyticum.